# A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct03843918/  
OnCo record `nct03843918` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Lapiteronel run by Laekna Limited, terminated.

## Summary

A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT03843918 by Laekna Limited, with 33 participants enrolled, started 2019-04-05, primary completion reached 2023-10-09. Conditions recorded: Prostate Cancer Metastatic. Interventions recorded: LAE001. Reason given for stopping: This is phase I/II study, phase I study completed, phase II study started and enrolled 1 patient. Company strategy consideration to terminated phase 2 study finally.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03843918
- Phase: 1/2
- Setting: A Phase I/II Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
- Sponsor: Laekna Limited
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT03843918: https://clinicaltrials.gov/study/NCT03843918

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Lapiteronel](https://onco.cc/drugs/lapiteronel/)
- companies: [Laekna Therapeutics](https://onco.cc/companies/laekna-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct03843918.json